InMed and Mentari amend merger agreement, file Form S-4
The companies clarified deal sequencing, exchange ratio impacts, and tax treatment as InMed targets a fourth-quarter 2026 close.
SEC filing
Latest
Friday, July 10
VYNE declares special dividend tied to pending Yarrow Bioscience merger
VYNE Therapeutics set a $16.5 million cash dividend ahead of its planned merger with Yarrow, with closing expected around July 24, 2026.
SEC filing
Sunshine Biopharma settles dispute with former Nora Pharma president
The company will pay Malek Chamoun about CAD$1.5 million to resolve a disagreement tied to his former role at its Nora Pharma subsidiary.
SEC filing
AstraZeneca posts NATRON Phase III benralizumab results; registers ROSY-S anifrolumab rollover study
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular events
Apnimed files for IPO as FDA reviews Oxnimbi NDA for sleep apnea
The company disclosed FDA feedback questioning whether its Phase 3 data show a clinically meaningful benefit, even as it seeks Nasdaq listing under "APMD."
SEC filing
Novartis posts BioItaLEE and China ribociclib results; registers three new studies
SL Science seeks FDA orphan drug status for GDT cell therapy in glioblastoma
The Taiwan-based biotech submitted its request for the gamma delta T cell product on March 30, 2026, and the FDA's orphan products office has acknowledged receipt.
SEC filing
Thursday, July 9
Annovis Bio completes enrollment in Phase 3 buntanetap trial for early Alzheimer's
The 850-patient study exceeded its original enrollment target, with symptomatic data expected in Q1 2027 and disease-modifying data in Q1 2028.
SEC filing
FDA approves Amneal's sodium bicarbonate injection NDA220790
The new drug application for an intravenous sodium bicarbonate solution received original approval as a Type 5 new formulation or new manufacturer submission.
Drugs@FDA
FDA approves Sarclisa Escena, a new dosage form from Sanofi
The agency cleared BLA761445 for isatuximab-irfc under the brand name Sarclisa Escena, with an original approval dated July 9, 2026.
Drugs@FDA
AstraZeneca and Ionis report Wainua misses primary endpoint in CARDIO-TTRansform Phase III
The trial in transthyretin-mediated amyloid cardiomyopathy did not show a statistically significant benefit over placebo, though a monotherapy subgroup showed a nominally significant effect.
SEC filing
Inventiva completes EIB warrant restructuring, issues new warrants to bank
The company swapped remaining legacy EIB warrants for a simplified instrument, part of a broader refinancing tied to lanifibranor's MASH program.
SEC filing
Ionis and AstraZeneca's eplontersen misses primary endpoint in Phase 3 ATTR-CM trial
The CARDIO-TTRansform study failed to show a statistically significant benefit over placebo, though a monotherapy subgroup showed a nominally significant result.
SEC filing
PMGC subsidiary NorthStrive Defense Tech secures exclusive license tied to aerospace patent
The license grants rights to a patented technology and know-how for use in aerospace and defense applications, with royalties and milestone obligations attached.
SEC filing (2)
MetaVia completes dose titration in Phase 1 obesity trial of DA-1726
All active patients in both Part 3 cohorts reached their highest target doses, with topline data still expected in the fourth quarter of 2026.
SEC filing
Biohaven announces leadership changes as Car retires, Pirman promoted
Biohaven's chief scientific officer moves to a new part-time innovation role while David Pirman takes over discovery operations, effective July 13, 2026.
SEC filing
Vera Therapeutics names new Chief Regulatory Officer
William Turner steps down from the CRO role and moves to a special advisor position, with Nancy Bowman set to replace him.
SEC filing
Kyverna amends Oxford Finance loan facility, pushes back Term A deadline
Kyverna will pay a $187,500 fee to extend its remaining Term A loan draw window to the end of 2026, with further changes tied to full drawdown.
SEC filing
Traws Pharma stockholders approve share increase, elect directors at annual meeting
At its July 8, 2026 annual meeting, Traws Pharma stockholders approved a 2,000,000-share increase to the company's incentive compensation plan and elected seven directors.
SEC filing
FibroBiologics adds retired NASA astronaut Kate Rubins to board of directors
The Houston biotech named Kathleen Rubins, Ph.D. a Class III director effective July 8, 2026, following Matt Link's resignation from the board.
SEC filing
Aligos posts results for ALG-097558 renal impairment PK study, trial completed
Nurix strikes $2.3 billion Roche pact for BTK degrader bexobrutideg
Roche deal brings $700 million upfront and expands the drug into CSU and MS as Nurix advances its CLL pivotal trials.
SEC filing
Novo Nordisk registers Phase 1 study of oral obesity candidate NNC6022-0004
ImmuCell reports 11.5% Q2 2026 sales growth, driven by domestic demand
The animal health company posted preliminary second-quarter sales of $7.2 million, with domestic growth offsetting a decline in international sales.
SEC filing
Boehringer Ingelheim's Phase I obesity drug BI 3034701 trial listed as active, not recruiting
Travere's chief accounting officer to retire, controller named as successor
Sandra Calvin plans to step down as CAO and PAO after filing the 2027 annual report, with John Torell expected to take.
SEC filing
Bone Biologics closes $3 million private placement priced at-the-market
The spine biologics company sold shares and warrants to a single institutional investor, with potential added proceeds of up to $6 million if warrants are exercised.
SEC filing
Amlogenyx discloses $10 million raised in convertible note offering
The Novato, California biotech reported selling half of a planned $20 million offering to two investors as of a Form D filed with the SEC.
SEC filing
Sanofi opens new Alzheimer's Phase 2 for SAR448851 alongside gastric cancer trial
Incyte-linked ruxolitinib trials post results; both MGH and UT Southwestern studies report
Glenmark's generic nintedanib esylate capsules (ANDA212555) listed as approved, with July 2021 appro
Wednesday, July 8
Tarsus acquires iRenix Medical for up to $565 million to add late-stage eye drug IRX-101
The deal brings Tarsus a Phase 2b/3-tested ocular antiseptic aimed at reducing pain and corneal damage from intravitreal injections, with a Phase 3 study planned to start enrolling in the first half of 2027.
SEC filing
OKYO Pharma gets FDA Type D feedback, moves urcosimod into global Phase 3 for eye pain
The FDA meeting outcome supports a single-dose trial design and a possible single-trial path to registration for the neuropathic corneal pain candidate.
SEC filing
Chemomab and Scipher Medicine agree to merge, target RA precision medicine trial
The combined company, to be named Scipher Medicine, plans a Phase 2 trial of nebokitug in rheumatoid arthritis guided by an AI patient-selection platform, with a readout expected in H1 2028.
SEC filing
Moderna adds former Biogen CFO Michael McDonnell to board
Moderna appointed Michael McDonnell to its Board of Directors and Audit Committee, effective July 8, 2026, as the company prepares for potential product launches.
SEC filing
Evolus licenses IBSA's Profhilo for U.S. skin quality market
Evolus will handle U.S. development and regulatory work for the European skin-boosting injectable, with no upfront payment to IBSA.
SEC filing
GSK terminates collaboration agreement with Alector after two drug setbacks
GSK's termination follows failed trials for both progranulin-elevating antibodies developed under the partnership, and Alector separately paid off its outstanding loan.
SEC filing
Nektar registers Phase 3 atopic dermatitis trial for rezpegaldesleukin
NewcelX names diabetes cure researcher Dr. Camillo Ricordi to scientific advisory board
The Zurich-based cell therapy company said the move follows a successful FDA Type B Pre-IND meeting for its lead program, NCEL-101.
SEC filing
Lifeward Ltd. files Form D for $11.16 million offering under Rule 506(b)
The Hudson, Massachusetts-based company reported five investors in a securities sale that began July 6, 2026, with no sales commissions paid.
SEC filing
AbbVie registers two real-world studies for atogepant and mirvetuximab soravtansine-gynx
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) updates registry record NCT0768927
Aura Biosciences names Jeremy Bender to board of directors
The clinical-stage oncology company added Bender, former Day One Biopharmaceuticals CEO, as it advances its lead candidate bel-sar toward potential approval.
SEC filing
Seres Therapeutics stockholders approve incentive plan increase at reconvened annual meeting
The meeting, adjourned in June for lack of quorum, reconvened on July 8, 2026 with stockholders backing three director nominees and a 900,000-share increase to the 2025 incentive plan.
SEC filing
Ovid Therapeutics names Charles Carter CFO as Jeffrey Rona departs
Ovid's board appointed Carter to succeed Rona effective July 6, 2026, following what the company said was a mutual decision on Rona's exit.
SEC filing
MacroGenics board member Karen Ferrante to resign effective September 1, 2026
Ferrante notified the board of her departure on July 1, 2026, with the company saying the move was unrelated to any dispute over its operations.
SEC filing
Alkermes and Amneal terminate VIVITROL authorized generic supply deal
The companies ended their September 2025 agreement on July 6, 2026, after Amneal declined to order product under the arrangement.
SEC filing